Is it safe to use a GLP‑1 receptor agonist (e.g., liraglutide) with Camzyos (mavacamten)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonists Can Be Used with Camzyos, But Requires Careful Cardiac Monitoring

Yes, it is safe to use GLP-1 receptor agonists with Camzyos (mavacamten) in most patients, but this combination requires vigilant monitoring of left ventricular ejection fraction (LVEF) due to overlapping cardiac effects. The FDA label for Camzyos does not list GLP-1 RAs as contraindicated or requiring avoidance, and there are no documented drug-drug interactions between these medication classes 1.

Key Safety Considerations

Camzyos-Specific Cardiac Risks

Camzyos carries a black box warning for heart failure due to systolic dysfunction. The drug:

  • Should not be initiated in patients with LVEF <55% 1
  • Causes a mean reduction in LVEF of 4% during treatment 1
  • Led to reversible LVEF reductions to <50% in 6% of trial patients 1
  • Requires enrollment in a REMS program with mandatory LVEF monitoring 1

GLP-1 RA Cardiac Effects in Heart Failure

While GLP-1 RAs have demonstrated cardiovascular benefits in patients with atherosclerotic disease, their track record in heart failure with reduced ejection fraction (HFrEF) is concerning:

  • The FIGHT trial showed liraglutide tended to increase heart failure hospitalization risk (HR 1.30,95% CI 0.89-1.88) in patients with recent HF decompensation 2
  • The LIVE trial found more serious cardiac adverse events with liraglutide versus placebo (10.0% vs 3.0%, p=0.04) in stable HFrEF patients 3
  • GLP-1 RAs have shown no benefit in preventing HF hospitalization across large cardiovascular outcomes trials 2
  • These agents increase heart rate by 3-10 beats/min, which may be problematic in already compromised cardiac function 2

Clinical Implementation Algorithm

Before initiating combination therapy:

  1. Verify baseline LVEF ≥55% - This is mandatory per Camzyos labeling 1
  2. Assess for existing heart failure - If HFrEF is present, GLP-1 RAs offer no proven benefit and may increase risk 3, 2
  3. Document indication for GLP-1 RA - Ensure appropriate use for diabetes or obesity, not cosmetic weight loss

During combination therapy:

  1. Monitor LVEF per Camzyos REMS protocol:

    • Before treatment initiation
    • At 4 weeks after starting
    • At 12 weeks
    • With every dose adjustment
    • If any signs/symptoms of heart failure develop 1

  2. Watch for additive cardiac effects:

    • New or worsening dyspnea
    • Fatigue or exercise intolerance
    • Peripheral edema
    • Tachycardia (both drugs can affect heart rate)

  3. Interrupt Camzyos immediately if LVEF drops below 50% - All patients in trials who developed reduced LVEF recovered after drug interruption 1

Drug Interaction Considerations

The primary concern with Camzyos is CYP2C19 and CYP3A4 interactions, not GLP-1 RAs 1. However:

  • Proton pump inhibitors (omeprazole, esomeprazole) are moderate CYP2C19 inhibitors and can increase Camzyos exposure 1
  • Many patients on GLP-1 RAs use PPIs for GI side effects - this creates an indirect safety concern
  • If PPIs are needed, dose adjustment of Camzyos may be required per the drug label 1

Special Populations

Patients with hypertrophic cardiomyopathy (HCM):

  • Real-world data shows Camzyos is highly effective with 90% achieving hemodynamic response 4
  • New-onset atrial fibrillation occurred in 7.3% of patients on Camzyos 4
  • GLP-1 RAs have not been specifically studied in HCM populations

Patients with obesity:

  • Weight loss from GLP-1 RAs may be beneficial in obese HCM patients 4
  • However, ensure weight loss is medically appropriate and supervised 5

Bottom Line Recommendation

Proceed with combination therapy if:

  • LVEF is ≥55% at baseline
  • No history of HFrEF or recent heart failure decompensation
  • Patient can comply with mandatory LVEF monitoring
  • Clear medical indication exists for GLP-1 RA (diabetes or obesity with BMI ≥30 or ≥27 with comorbidities)

Exercise extreme caution or avoid if:

  • Any history of systolic dysfunction or HFrEF
  • LVEF 55-60% (borderline - consider alternative therapies)
  • Recent heart failure hospitalization
  • Unable to comply with REMS monitoring requirements

The combination is not contraindicated, but the overlapping potential for cardiac effects demands heightened vigilance beyond standard Camzyos monitoring protocols.

References

Related Questions

Can a GLP‑1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide) alter vaginal pH and cause gray discharge?
Can GLP-1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, semaglutide) increase parathyroid hormone secretion and contribute to mild hypercalcemia in a patient with serum calcium of 10.7 mg/dL?
Can use of a GLP‑1 receptor agonist combined with aggressive weight loss cause scurvy?
Can a patient taking hydroxychloroquine safely be started on a GLP‑1 receptor agonist?
Can GLP‑1 receptor agonists (e.g., liraglutide, semaglutide, exenatide) cause changes in the menstrual cycle of a perimenopausal woman (approximately 45–55 years old)?
What is the appropriate management for conjunctivitis that is not responding to topical antibiotics?
What is the recommended medication regimen for cutaneous anthrax in an otherwise healthy adult?
What is the likely diagnosis for a patient with resting heart rate in the 60 bpm range, sleeping heart rate in the 40 bpm range, and standing heart rate increasing to 140 bpm, and what are the recommended management steps?
Should Eliquis (apixaban) be combined with Plavix (clopidogrel) for treatment of deep vein thrombosis (DVT)?
Given a patient with a supine heart rate of about 60 bpm, a nocturnal dip to about 40 bpm, a standing heart rate of about 140 bpm, and typical orthostatic symptoms for more than three months, is a tilt‑table study required to diagnose postural orthostatic tachycardia syndrome?
In a patient with a CD4 count <200, how should neurosyphilis be evaluated and treated, and what opportunistic infection prophylaxis is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.